Recent Updates
Recently added Catalysts
WVE Positive Sentiment

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

Key Takeaway: Wave Life Sciences Ltd. will present at the Cantor 2026 Global Healthcare Conference. CEO Paul Bolno is scheduled for a fireside chat on September 10, 2026. The event will be accessible via a live webcast, with a replay available afterward. Wave continues to advance its RNA medicines platform targeting various diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Wave Life Sciences is actively engaging with investors.
  • The company is focused on innovative RNA medicines.
  • The upcoming presentation highlights their commitment to scientific breakthroughs.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
33.2%
average across 9 past catalysts
Cash runway
~27 mo
Minimal dilution risk
Lead asset
WVE-N531
Phase 2 · Duchenne Muscular Dystrophy

Full Press Release Details

CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Cantor 2026 Global Healthcare Conference in New York City on Thursday, September 10, 2026 at 9:45 a.m. ET.
A live webcast of the presentation can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of this presentation will be archived and available on the site for a limited time following the event.
About Wave Life Sciences Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Contact: Kate Rausch VP, Corporate Affairs and Investor Relations +1 617-949-4827

Investors: James Salierno Director, Investor Relations +1 617-949-4043 InvestorRelations@wavelifesci.com

Media: Katie Sullivan Senior Director, Corporate Communications +1 617-949-2936 MediaRelations@wavelifesci.com

Frequently Asked Questions

When is Wave Life Sciences presenting at the conference?

Wave Life Sciences will present on September 10, 2026.

Who is representing Wave Life Sciences at the event?

CEO Paul Bolno will participate in the analyst-led fireside chat.

How can I access the presentation?

The presentation will be available via a live webcast on their website.

What is Wave Life Sciences focused on?

The company focuses on RNA medicines to address various health disorders.

Last updated: Sep 3, 2026